Follicular Versus Luteal Pipelle in Repeated Implantation Failure Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pipelle was found to increase pregnancy and implantation rates in women undergoing IVF treatment in general, and in particular in repeated implantation failure (RIF). However, there is virtually no data regarding the optimal timing for the pipelle.

The current study aims to compare between follicular and luteal pipelle on pregnancy rate in RIF patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Repeated Implantation Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pipelle, luteal, follicular, implantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Women diagnosed with RIF who are going to start a new IVF treatment

Exclusion Criteria

Known hydrosalpinx body mass index (BMI) \>29 kg/m2 or \<18 kg/m2 Low ovarian response

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ido Ben-Ami, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofeh Medical Center, Zerifin, Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

139/13

Identifier Type: -

Identifier Source: org_study_id